Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the Kidney Disease: Improving Global Outcomes (KDIGO).

ACKNOWLEDGEMENT

This activity is supported by an independent educational grant from Travere Therapeutics, Inc.

TUITION

Complimentary

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Friday, November 12, 2021 from 12:00noon – 1:00pm ET: IgAN: New Guidelines and Emerging Treatments to Reach Proteinuria Goals and Slow Decline in Kidney Function
Friday, December 17, 2021 from 12:00noon – 1:00pm ET: FSGS: New Guidelines and Emerging Treatments to Reduce Proteinuria to Goals and Slow Decline in Kidney Function

Enduring Material

The enduring material will be available from November 12, 2021 to December 17, 2022.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

IgAN: New Guidelines and Emerging Treatments to Reach Proteinuria Goals and Slow Decline in Kidney Function

• Describe the disease burden experienced by children and adults with IgAN, including the consequences of late diagnoses and the limitations of current therapies
• Define the pathophysiology of IgAN, specifically as it relates to the role of ET1 and RAAS on proteinuria regulation
• Describe the mechanism of action, efficacy and safety data, and potential place in care of emerging dual AT1/ETA blockers to reduce proteinuria to clinically meaningful goals and slow renal function decline in IgAN
• Apply updated KDIGO guidelines for the diagnosis of IgAN, assessing patient risk for rapid disease progression using clinical history, laboratory findings, and renal biopsy

FSGS: New Guidelines and Emerging Treatments to Reduce Proteinuria to Goals and Slow Decline in Kidney Function

• Describe the disease burden experienced by children and adults with FSGS, including the consequences of late diagnoses and the limitations of current therapies
• Define the pathophysiology of FSGS, specifically as it relates to the role of ET-1 and RAAS on proteinuria regulation
• Explain the mechanism of action and efficacy and safety data for emerging dual AT1/ETA blockers, and describe how these agents may help patients with primary or genetic FSGS reach the clinically meaningful outcome of partial proteinuria reduction and rate of eGFR slope decline
• Apply updated KDIGO guidelines for the diagnosis and prognosis of FSGS, differentiating primary, secondary, and genetic FSGS

TARGET AUDIENCE

The intended audience for this activity are nephrologists. The secondary audiences are primary care/internal medicine physicians.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 2 hours to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ClinicalSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon) KDIGO Knowledge Translation Lead Clinical Professor of Medicine University of Illinois at Chicago College of Medicine/Advocate Christ Medical Center Section of Nephrology	Consulting Fees (e.g., advisory boards): Bayer, Vifor Ownership Interest: Fresenius Joint Venture Honoraria: UpToDate, McGraw-Hill Publishing, Elsevier Publishing, Wolters Kluwer Publishing, National Kidney Foundation Scientific Advisor or Membership: Journal of Clinical Liipidology, International Urology and Nephrology Journal, Journal of Vascular Access, Prescribers Letter, Renal and Urology News, ASN Kidney News, Reviews in Endocrinology and Metabolic Disorders, American Journal of Kidney Diseases Blog, American Heart Association Kidney and Cardiovascular Disease Leadership Group and SCILL Committee Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Astra Zeneca, Bayer, Otsuka, Vifor
Sharon Adler, MD Professor of Medicine David Geffen School of Medicine at UCLA Investigator, The Lundquist Institute Chief, Division of Nephrology and Hypertension at Harbor-UCLA Medical Center Program Director, Nephrology Fellowship Training Program at Harbor-UCLA Medical Center	Consulting Fees (e.g., advisory boards): AstraZeneca, Aurinia, Bayer, Calliditas, ChemoCentryx, MorphoSys, Omeros, Travere Therapeutics, Zyversa Contracted Research: AstraZeneca, Bayer, Calliditas, ChemoCentryx, MorphoSys, Omeros, Travere Therapeutics
Jonathan Barratt, PhD, FRCP The Mayer Professor of Renal Medicine Honorary Consultant Nephrologist University of Leicester	Consulting Fees (e.g., advisory boards): Alnylam Pharmaceuticals, Argenx, Astellas Pharma, BioCryst Pharmaceuticals, Calliditas Therapeutics, Chinook Therapeutics, Dimerix, Galapagos NV, Novartis, Omeros, Travere Therapeutics, UCB, Vera Therapeutics, Visterra Contracted Research: Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos NV, GSK, Novartis, Travere Therapeutics
Rosanna Coppo, MD, FERA Past Director Nephrology, Dialysis, and Transplantation Regina Margherita Children's Hospital Fondazione Ricerca Molinette	Consulting Fees (e.g., advisory boards): Amgen, Argenx, Calliditas Therapeutics, Novartis, Otsuka, Reata, Recordati, Travere Therapeutics, UpToDate
Jai Radhakrishnan, MD, MS Professor of Medicine Columbia University Irving Medical Center	Consulting Fees (e.g., advisory boards): Angio, Travere Therapeutics Contracted Research: Goldfinch Bio, Travere Therapeutics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner	Reported Financial Relationship
Carole Drexel Medical Director PlatformQ Health Education, LLC	None
Eve Wilson Medical Director PlatformQ Health Education, LLC	None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive.com at 877-394-1306 or at Support@ClinicalSeriesLive.com.